Gilead Sciences Inc (GILD) Actualités

Form 144 - Report of proposed sale of securities

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention

– One Application Seeks European Commission Authorization; Other Application Would Facilitate Availability in Low- and Lower-Middle-Income...

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis

– Now Approved, Seladelpar Can Provide an Important Treatment Option for People Living With the Rare Liver Disease in the European Economic Area...

Form 4 - Statement of changes in beneficial ownership of securities

Gilead Sciences to Present at Upcoming Investor Conferences

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual...

Form 144 - Report of proposed sale of securities

U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review

– If Approved, Lenacapavir Would Be the First and Only Twice-Yearly HIV Prevention Choice – – FDA to Review Applications Under Priority Review...

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 13F-HR - Quarterly report filed by institutional managers, Holdings

Form 144 - Report of proposed sale of securities

Gilead Sciences Announces 2.6 Percent Increase in First Quarter 2025 Dividend

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 2.6% in the company’s...